enGene Therapeutics Presents Pivotal LEGEND Trial Data for Detalimogene in High-Risk NMIBC
enGene Therapeutics Inc. (ENGN) held a conference call on May 7, 2026, to discuss pivotal cohort data from its Phase II LEGEND trial. The trial evaluates detalimogene voraplasmid, also known as detalimogene, for treating high-risk Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ. Key company executives, including CEO Ronald H. Cooper and Chief Medical Officer Hussein Sweiti, presented the findings to analysts from major financial institutions such as Jefferies, Leerink Partners, and Wells Fargo Securities. The discussion focused on the clinical outcomes and potential commercial implications of the therapy. This update represents a significant milestone for enGene Therapeutics as it advances its pipeline for bladder cancer treatments. The company emphasized the importance of these results for patients who have not responded to standard BCG therapy, highlighting the potential for detalimogene to address an unmet medical need in this specific patient population. The event underscores the company's progress in clinical development and its engagement with the investment community regarding future commercialization strategies.
Wire timeline
enGene Therapeutics Presents Pivotal LEGEND Trial Data for Detalimogene in High-Risk NMIBC
enGene Therapeutics Inc. (ENGN) held a conference call on May 7, 2026, to discuss pivotal cohort data from its Phase II LEGEND trial. The trial evaluates detalimogene voraplasmid, also known as detalimogene, for treating high-risk Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ. Key company executives, including CEO Ronald H. Cooper and Chief Medical Officer Hussein Sweiti, presented the findings to analysts from major financial institutions such as Jefferies, Leerink Partners, and Wells Fargo Securities. The discussion focused on the clinical outcomes and potential commercial implications of the therapy. This update represents a significant milestone for enGene Therapeutics as it advances its pipeline for bladder cancer treatments. The company emphasized the importance of these results for patients who have not responded to standard BCG therapy, highlighting the potential for detalimogene to address an unmet medical need in this specific patient population. The event underscores the company's progress in clinical development and its engagement with the investment community regarding future commercialization strategies.
All Articles on Seeking Alpha